Answers are grounded in this paper and cite their sources.
Hypophosphatemic osteomalacia is a recognized complication of repeated intravenous iron infusions in patients with preserved kidney function. It results from an iron-induced rise in intact fibroblast growth factor 23 (FGF23), which causes renal phosphate wasting. It is rarely considered in hemodialysis patients, in whom hyperphosphatemia is the rule. We report the case of a 62-year-old anuric woman on hemodialysis for 22 years for polycystic kidney disease who had received 40 infusions of 200 mg iron sucrose (8 g in total) as maintenance therapy over 10 years, the last one two months before admission. She received no phosphate binder, vitamin D, or calcimimetic. She was referred for diffuse bone pain and proximal muscle weakness of 11 months' duration. Predialysis serum phosphate was low (0.40 and 0.52 mmol/L), alkaline phosphatase was elevated (2.35 times the upper limit of normal), and parathyroid hormone was 335 pg/mL, within the recommended dialysis target; 25-hydroxyvitamin D and serum calcium were normal. Review of her medical records revealed unexplored hypophosphatemia for at least five years. Intact FGF23 was low to low-normal (10.4 and 27.2 pg/mL), which is markedly inappropriate for a hemodialysis patient. Radiographs showed pseudofractures (Looser zones) and biconcave vertebrae. After iron withdrawal and oral phosphate supplementation, serum phosphate and alkaline phosphatase normalized, and pain decreased from 7/10 to 2/10 at eight months. The association with iron sucrose was rated as possible (Naranjo score of 3), and its mechanism remains unexplained, as the FGF23-mediated renal pathway cannot operate in anuria. Hypophosphatemia in a hemodialysis patient is never trivial and should prompt a search for osteomalacia.
No takes yet. Share an insight, caveat, or question.
TOLBIX et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: